LexaGene Announces Advancements to its Sample Preparation Cartridge for the Veterinary Market
March 29 2022 - 7:45AM
LexaGene Holdings Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
has commercialized the MiQLab® System, a fully automated rapid
pathogen testing device, today announced advancements to its sample
preparation cartridge for processing complex samples.
LexaGene’s MiQLab® System is designed to process liquid samples
from companion animals used in the diagnosis of infections such as
urinary tract infections (UTI’s) and skin infections. The System,
equipped with a MiQLab® Bacterial and AMR panel, screens samples
for 10 common pathogens and 33 markers for antimicrobial resistance
(AMR) testing. These AMR tests target genes that confer resistance
to four classes of first-line therapeutics, namely tetracyclines,
beta lactams, sulfa-TMP, and lincosamides.
Dr. Jack Regan, LexaGene’s CEO and Founder, stated, “Some sample
types are easily processed for PCR testing, such as nasal swab
samples, whereas other sample types, contain inhibitors that
interfere with PCR. To better handle more complex samples, we have
recently embedded a new chemistry into our sample preparation
cartridge that greatly improves the MiQLab System’s ability to
process samples that contain a significant percentage of blood,
which is a powerful inhibitor of PCR. We are excited about this
advancement and believe the new sample preparation cartridge
broadens our testing capabilities for companion animals.”
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab® system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
For inquiries: 800.215.1824 | ir@lexagene.com or info@lexagene.com
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024